Publications

Category: Publications 24 August 2022

Author

How to use biosimilars and generic NBCDs as DMTs for Multiple Sclerosis?

Co-authored by Christian Wolf:

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova, and Jeffrey A Cohen.

Mult Scler J. 2022; 135245852211162. (abstract).

Read more ...

Category: Publications 14 June 2022

Author

Phase II for a 2nd-generation DHDOH inhibitor

Co-authored by Christian Wolf:

A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.

Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler.

Ann Clin Transl Neur 2022;9:977–87 (full text).

Read more ...

Category: Publications 15 April 2022

Author

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?

Co-authored by Christian Wolf:

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?

Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C.

Front Neurol 2022; 13:844873 (full text).

Read more ...

Category: Publications 21 January 2022

Author

Combination is key – new treatments for lung and colon cancer?

Researchers from the Experimental Pharmacology and Oncology (EPO) in Berlin-Buch in cooperation with academic partners identified new experimental approaches to treat therapy resistant cancer.

Read more ...

Category: Publications 19 May 2021

Author

Patient safety is paramount in drug trials

In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.

Read more ...

Category: COVID-19 19 April 2021

Author

Do we still need challenge trials with COVID-19?

A response to a Human Challenge statement in the BMJ by Nir Eyal and colleagues.

Read more ...

Category: Publications 6 April 2021

Author

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

Read more ...

Category: Publications 18 March 2021

Author

A new era for UK-Japanese scientific relations

As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in the Pharmaceutical Market Europe and PMLive.

Read more ...

Category: Publications 19 January 2021

Author

Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.

Co-authored by Christian Wolf

Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.

Neurology. 20219; 96:e376-e386. https://doi.org/10.1212/WNL.0000000000011275.

 

Category: Publications 18 November 2020

Author

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

Co-authored by Christian Wolf

Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L.

Multiple Sclerosis Journal 2020; Nov 18:1352458520971819, https://doi.org/10.1177/1352458520971819 (open access).